Bioresorbable vascular scaffolds in coronary chronic total occlusions: clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study)
- 1 May 2019
- journal article
- research article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 15 (1) , 99-107
Abstract
Aims: Percutaneous treatment of coronary chronic total occlusion (CTO) is associated with important arterial remodelling after successful recanalisation. Bioresorbable vascular scaffold (BVS) implantation in CTO has been shown to be feasible and can be of interest when the scaffold achieves complete bioresorption. We sought to evaluate the three-year results in terms of clinical events, serial imaging outcomes and vasomotion response in CTO lesions successfully treated with BVS. Methods and results: A total of 33 patients (35 CTO lesions) successfully treated with BVS were included in the ABSORB-CTO study. Clinical outcomes, quantitative coronary angiography (QCA) and optical coherence tomography (OCT) assessment were analysed at one- and three-year follow-up. Vasomotion examination was also performed at three years. At three years, cumulative target vessel reocclusion was observed in four lesions (11.4%). By QCA, the in-scaffold segment presented a lumen loss of 0.23 +/- 0.46 mm compared with the baseline procedure (p=0.001) and a lumen gain of 0.05 +/- 0.29 mm between one and three years (p=0.220). By OCT, the mean neointimal area stenosis progressed from 11.45% at 12 months to 17.10% at 36 months (p<0.001) and mean scaffold area increased continuously at 12 (+12%; p<0.001) and at 36 months (+14.85%; p=0.001). Late acquired incomplete scaffold apposition (LAISA) observed at 12 months in three patients was completely undetectable at three years. Most cases responded to endothelium-dependent vasomotor stimuli (69%). Vasoconstriction to acetylcholine was the predominant response (45%). Conclusions: Successful recanalisation of coronary CTO with BVS implantation is associated with favourable clinical and imaging outcomes. Despite vessel motility restoration, successfully treated CTOs remain with signs of endothelial dysfunction.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trialThe Lancet, 2016
- Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total OcclusionsCirculation: Cardiovascular Interventions, 2016
- One-Year Results of Bioresorbable Vascular Scaffolds for Coronary Chronic Total OcclusionsThe American Journal of Cardiology, 2016
- Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot studyEuroIntervention, 2015
- Serial changes of coronary endothelial function and arterial healing after paclitaxel-eluting stent implantationCardiovascular Intervention and Therapeutics, 2015
- Outcomes and Computed Tomography Scan Follow-Up of Bioresorbable Vascular Scaffold for the Percutaneous Treatment of Chronic Total Coronary Artery OcclusionThe American Journal of Cardiology, 2015
- Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusionInternational Journal of Cardiology, 2015
- Assessing Bioresorbable Coronary DevicesJACC: Cardiovascular Imaging, 2014
- Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery StenosisJACC, 2011
- Retrograde approach to coronary chronic total occlusions: preliminary single European centre experienceEuroIntervention, 2007